Cantor Fitzgerald Keeps Their Buy Rating on Invivyd (IVVD)

Tip Ranks
2025.11.07 15:07
portai
I'm PortAI, I can summarize articles.

Cantor Fitzgerald analyst Joshua Schimmer has maintained a Buy rating on Invivyd (IVVD) with a price target of $10.00. Schimmer, who specializes in the Healthcare sector, has an average return of 15.5% and a success rate of 52.43% on his stock recommendations. The overall analyst consensus for Invivyd is a Moderate Buy, also with a $10.00 average price target.

In a report released yesterday, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on Invivyd, with a price target of $10.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Schimmer covers the Healthcare sector, focusing on stocks such as Cabaletta Bio, Palvella Therapeutics, and Rocket Pharmaceuticals. According to TipRanks, Schimmer has an average return of 15.5% and a 52.43% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Invivyd with a $10.00 average price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.